Free breaking news alerts from StreetInsider.com!
Applied UV, Inc. (NASDAQ: AUVI), a pathogen elimination technology company, applies the power of narrow-range ultraviolet ("UVC") to surface areas and catalytic bioconversion technology to purify air for safety and thoroughness , He Auto announced that its exclusive distribution partner in Thailand will install Airocide® devices at the Armed Forces Institute of Medical Sciences ("AFRIMS") in Bangkok, Thailand, to help create a safer and cleaner environment for tourists and staff. AFRIMS is the biomedical research organization of the Walter Reed Army Research Institute ("WRAIR") of the U.S. Army. The mission of AFRIMS is to conduct breakthrough research on military medicine in Southeast Asia and the Indian subcontinent countries, focusing on diseases related to infectious pathogens.
AFRIMS has dual headquarters of the Royal Thai Army and the U.S. Army, of which the U.S. part is a special foreign activity of WRAIR in Washington, DC. Since 1893, WRAIR has been a leader in addressing major threats to soldiers' readiness and lethality, such as disease and combat injuries. WRAIR's extensive research capabilities in its Washington, DC, regional, and expeditionary laboratories work collaboratively to provide soldiers with the best medical protection and support before, during, and after deployment by addressing long-standing and emerging threats. Although WRAIR's research focuses on soldier health, its products have important civilian applications and have saved countless lives around the world.
With the ongoing battle against COVID-19 and the recent emergence of new Omicron strains around the world, AFRIMS is installing the Airocide® system to control airborne diseases and protect critical areas within the facility. The installation of Airocide GCS series devices in research institutions shows that the Thai medical community is committed to seeking and providing the best air purification and disinfection technology to protect their employees.
Owning the only known FDA-listed Class II medical device that has been clinically proven to kill COVID 19, Applied UV continues to strengthen its distributor relationships in Southeast Asia and around the world to satisfy its air and surface infections Controlled demand products. The facilities installed in this leading military research facility and other global facilities (JetBlue Air Park, Boston Red Sox, U.S. Army Aberdeen Proving Ground, Bangkok Municipal Government Lakrabang Hospital, Palace of Versailles) further prove the patent The efficacy and safety of Airocide air purification protect their employees, consumers and facilities by allowing these organizations to trust our products.
Max Munn, Founder and President of Applied UV said: "Installing our Airocide™ device in such a prestigious biomedical facility is another important milestone in our strategy to significantly improve our international commercial distribution capabilities and enter new markets. "Our Thai distributor Sithiporn Associates is one of the leading scientific equipment distributors in Thailand and the ASEAN region, and has been an excellent partner in commercializing our innovative and clinically proven pathogen elimination technology portfolio. Hospitals and research institutions are increasingly aware of the benefits of installing Airocide® systems in public spaces that can interrupt the spread of infectious pathogens in the air and quickly eliminate these microorganisms, while ensuring that the occupants are protected from any harmful by-products. "
Airocide® uses NASA's optimized photocatalytic oxidation ("PCO") technology, in which air and any contaminants are drawn into the Airocide® device from the room and introduced into the reaction chamber. UVC activates the proprietary photocatalyst embedded in the reaction chamber to start the photocatalytic process. In the reaction chamber, hydroxyl radicals and superoxide ions are generated and each contacted organic molecule is oxidized. The design of the reaction bed allows surface-bound free radicals to be exposed to nearly three hundred and sixty degrees to maximize the possibility of collisions with pathogens and other organic materials. Millions of hydroxyl free radicals converge and combine with pathogens (airborne bacteria, molds, fungi, mycotoxins, viruses, allergens) and carbon atoms in VOCs to convert organic matter into harmless steam and clean , Clear air.
The Airocide™ system was originally developed for NASA with the assistance of the University of Wisconsin-Madison. It is an airborne pathogen killing technology that uses a patented combination of UVC and a proprietary titanium dioxide-based photocatalyst. Airocide™ technology is listed as a FDA Class II medical device. After clinical verification and field testing, it can kill/remove/eliminate airborne pathogens and non-pathogenic microorganisms, allergens, odors, and harmful VOCs. It is suitable for medical care, hotels, etc. Various applications and industries, grocery chains, wineries, commercial real estate, schools, dental clinics and homes. Airocide® air purifier can be found on www.airocide.com
Applied UV focuses on the development and acquisition of technologies to address infection control in the healthcare, hotel, commercial and municipal markets. The company has two wholly-owned subsidiaries-SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's Data Driven Disinfection™ Connected Platform uses the power of ultraviolet light (UVC) to safely, completely and automatically eliminate pathogens and solve the challenge of health care acquired infection ("HAI"). The company’s Lumicide™ platform targets facilities with high customer churn rates, such as hospitals, hotels, commercial facilities, and other public places. UVC LEDs are used in a number of patented designs to control infections in and around high-traffic areas, including sinks and In the toilet, kill bacteria, viruses and other pathogens on the hard surface near the equipment. The company's patented Lumicide Drain, a disinfection device in the drainage pipe, is the only product on the market that addresses the dense location of this key pathogen. SteriLumen's Airocide™ product for air purification was developed by NASA and FDA and passed as a Class II medical device. It uses proprietary photocatalytic bioconversion technology to inhale air into the reaction chamber to transform destructive molds, microorganisms, dangerous pathogens, and destroy Sexual VOC and biogas are converted into harmless water vapor, which will not produce ozone or other harmful by-products. Airocide® applications include healthcare, hotels, grocery chains, brewing facilities, commercial real estate, schools, dental clinics, and homes.
For more information about Applied UV, Inc. and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; and, https://munnworks.com/ .
The information contained herein may contain "forward-looking statements." Forward-looking statements reflect current views on future events. When used in this press release, "anticipates", "believes", "estimates", "anticipates", "future", "intends", "plans" or the denial of these terms and similar expressions, because they are related to us or Our management confirms forward-looking statements. Such statements include, but are not limited to, the statements contained in this press release regarding Applied UV's management's views on its business strategy, future operating results, and liquidity and capital resource prospects. Forward-looking statements are based on the company’s current expectations and assumptions about its business, economy, and other future conditions. Because forward-looking statements are related to the future, they are subject to inherent uncertainties, risks and environmental changes that are difficult to predict. The company's actual results may differ materially from the results expected in the forward-looking statements. They are neither statements of historical facts nor guarantees of future performance. Therefore, we warn you not to rely on any of these forward-looking statements. Factors or events that may cause differences in the company's actual performance appear from time to time, and the company cannot predict all of these factors or events. The company cannot guarantee future results, activity levels, performance or achievements. Except as required by applicable laws (including U.S. securities laws), the company does not intend to update any forward-looking statements to make these statements consistent with actual results.
Applied UV Investor Relations Kevin McGrath TraDigital IR +1-646-418-7002 kevin@tradigitalir.com
View the source version on accesswire.com: https://www.accesswire.com/675424/Applied-UV-Continues-Global-Expansion-with-AirocideR-Installations-in-Thailand-at-the-Acclaimed-Armed-Forces -Research-Institute-of-Medical-Sciences-AFRIMS
Get full access to all new and archived articles, unlimited portfolio tracking, email alerts, custom news lines and RSS feeds-and more!